+1 973 564 7555 [email protected]
ISO 13485:2016   MDSAP MD 1243914-1
Global Offices:
  • U.S.
  • Germany
  • Russia
    • Moscow
    • Saint Petersburg
  • Poland
  • Czech Republic
0 Items
DRG International, Inc.
  • Products
    • DRG:HYBRiD-XL®
    • Hepcidin 25 (bioactive) HS
    • Salivary ELISA Kits
    • CHROMagar
    • RUO ELISAs
    • Health Canada Registered
    • Ameritox Labs
  • Distribution
  • Newsroom
    • News
    • Media
    • Events
  • Reference Library
  • About Us
    • General Information
    • History Timeline
  • Contact Us
Select Page

Iron deficient erythropoiesis might play key role in development of anemia in cancer patients

Abstract Introduction: Multifactorial pathogenesis is involved in anemia of cancer patients and defining the causes of anemia is not always simple.
Methods: The incidence of anemia among 4 major cancers (gastric, colorectal, lung cancer and hepatocellular carcinoma), and biochemical features of anemia using ferritin, CRP, hepcidin and soluble transferrin receptor (sTfR) were assessed. Anemia was defined either by hemoglobin (Hb) ≤11 g/dL or a drop of Hb 2 g/dL or more during anticancer treatment.
Results: Among the 345 patients including 152 lung cancer, 101 gastric cancer, 69 colorectal cancer and 23 hepatocellular carcinoma, 49 patients (14.2%) had anemia at their initial diagnosis of cancer. During treatment, 129 (37.4%) experienced anemia, and 34 (26.4%) were treated mostly by transfusion. Biochemical feature of anemia was examined with 39 patients' samples. When comparing to the reference value from general population, cancer patients showed numerically higher ferritin, sTfR, CRP and hepcidin level. Among the cancer patients, anemic patients had significantly higher ferritin (p = 0.050) and sTfR (p = 0.009) level compared to non-anemic patients.
Conclusion: Anemia is a common issue in cancer patients and is largely undertreated with sub-optimal diagnoses of cause. The rates of anemia increase significantly during anti-cancer treatment and appear to be largely associated with iron deficiency.

DRG product(s) used in the study above

You can view the product details and buy it now

Hepcidin -25 (bioactive) HS Park S., Jung CW1, Kim K1, Kim SJ1, Kim W.S., Jang J.H.,

Author Information

Oncotarget. 2015 Dec 15;6(40):42803-12.

Link: https://www.ncbi.nlm.nih.gov/pubmed/26517509

by Oleg Vishnevski | Dec 15, 2015

 
  • Events
  • News
  • Products
  • Uncategorized

DRG International, Inc.

841 Mountain Avenue
Springfield, NJ 07081 USA

Tel: +1-973-564-7555
Fax: +1-973-564-7556

Copyright © 2022.
DRG International Inc.
All Rights Reserved.
PCI Compliance Certification

Subsidiaries

  • USA
  • Germany
  • Russia – Moscow
  • Russia – St Petersburg
  • Poland
  • Czech Republic

Support

  • Order Information
  • Troubleshooting

Shortcuts

  • Login
  • Terms of Use
  • Privacy Policy
  • Privacy Preferences
  • Privacy Policy
  • Cookie Policy
  • Facebook
  • Twitter
  • Google
  • RSS
  • linkedin
  • instagram

Designed by Walnut St. Labs